HER2/ <i>neu</i> testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

Abstract

HER2 gene amplification is significantly associated with patient survival. HER2 gene amplification approaches might be an optimal HER2/neu testing strategy for the selection of HER2+ GC patients who are candidates to be treated with anti-HER2 therapies.